Growth Capital For Life Sciences & Healthcare

Telegraph Hill Partners is a venture capital firm dedicated to helping life science, medical device and healthcare companies achieve their growth objectives. When you work with us, you get an experienced team that knows how to drive growth and profitability while maintaining the vision and integrity of the organization.

We seek to partner with innovative companies by providing capital and strategic guidance to help them grow.

Our Strategy

Latest News & Announcements

First Criminal Conviction Secured with Next-Gen Forensic DNA Technology

June 4th, 2019|

San Diego, June 4, 2019—Verogen announced today that its DNA sequencing technology played a pivotal role in a recent court case in the Netherlands. This marks the first time that evidence generated with so-called “next generation” or massively parallel sequencing (MPS) has been used to secure a conviction in criminal courts of law. The defendant in the case was initially acquitted of sexual assault charges due to inconclusive DNA results generated with older technology (capillary electrophoresis). The prosecutor was granted an appeal, however, that allowed re-testing of the remaining biological evidence with contemporary MPS methods. The additional testing, conducted by Dutch forensic experts at Leiden University Medical Center (LUMC) using the MiSeq® sequencing system, yielded “highly informative DNA profiles,” according to Professor Peter de Knijff at LUMC. “Using the MiSeq we obtained a great deal more useful data, which proved extremely valuable as evidence in the case,” said Prof. de Knijff. “We could only have obtained these results using this sequencing platform.” Prof. de Knijff is considered a pioneer in the forensic use of MPS, which has already been widely implemented in other biological disciplines. For a number of years, Prof. de Knijff and other scientific leaders have argued that MPS offers significant advantages compared to the older methods commonly used in forensic laboratories. This recent court verdict supports that perspective. “This is an important milestone for acceptance of this technology as a powerful forensic tool,” said Brett Williams, Verogen CEO.  “Verogen is extremely proud to partner with leading forensic institutes like LUMC to assist the criminal justice system in developing or refuting genetic linkages.” Verogen, Inc. was established in 2017 to develop, sell and support forensic assays and software on Illumina sequencing platforms such as the MiSeq. The adjudication of this case is yet another sign of the accelerating global adoption of [...]

Cellmark and Verogen Collaborate to Make the Next Generation of Forensic DNA Analysis Available to UK Police

May 8th, 2019|

San Diego, May 8, 2019—Cellmark Forensic Services and Verogen have signed a collaboration agreement to establish Cellmark as a United Kingdom (UK) center of excellence for forensic next generation sequencing (NGS), also known as massively parallel DNA sequencing (MPS). Verogen, the leading provider of forensic MPS technology, completed its installation of a MiSeq FGx® platform at Cellmark’s Abingdon laboratory in February and the forensic validation exercise is now well underway.  Supported by the collaboration, Cellmark will be seeking to accredit MPS technology so that it can be introduced into forensic casework. “We are very excited about the potential benefits that this technology will bring to forensic investigations,” said David Hartshorne, Managing Director at Cellmark.  “The MPS technology will provide our scientists with far more detailed DNA information than is currently possible, which could be used to help resolve some of our most challenging forensic cases.” Within a single DNA test the technology will not only analyze Short Tandem Repeat (STR) markers that are currently used to populate the National DNA Database, but at the same time will provide Y-STR results (for male subjects), X-chromosome STR results, as well as a large number of Single Nucleotide Polymorphism (SNP) markers.  The SNP markers can assist with the certainty of identification and provide information about the appearance of the subject (phenotypic information) as well as data about their biogeographical ancestry.  MPS also has the potential to recover additional DNA information from the low level, degraded and mixed samples typical of forensic investigations but for which traditional methods can sometimes struggle to produce conclusive results. “MPS technology is already well established in other scientific fields,” said Brett Williams, CEO of Verogen, “and is now starting to prove its capability in forensic investigations with the first cases having gone through court.  We are delighted to be working in the UK [...]

Medpricer Signs Deal with Texas Children’s Hospital for Purchased Services Sourcing

May 8th, 2019|

May 8th, 2019 – Guilford, CT/Walnut Creek, CA – Medpricer, the leading purchased services cost management solution for the health care industry, announced today that Texas Children’s Hospital chose its mSource software platform to centralize its purchased service sourcing efforts. Texas Children’s Hospital is one of the largest pediatric hospitals in the nation and continues to grow and expand its services across the state of Texas. To meet these expanding needs, Texas Children’s created a Purchased Services Department to work with hospital stakeholders to identify which products and services are necessary to support patient care. Medpricer will provide the hospital with complete life cycle management tools for purchased services. mSource delivers analytics, e-RFP sourcing and Precision Benchmarks within one platform. This service can: Analyze more than 600+ spend categories to identify the suppliers that best meet their purchased services needs Run a complete RFP event online, from a call for proposals to negotiating and signing contracts Benchmark cost savings available within specific categories to determine what savings are available “Medpricer’s life cycle management expertise will complement Texas Children’s Purchased Services team,” said Medpricer CEO Chris Gormley. “By centralizing the entire purchased services sourcing process, we will help the hospital to maximize savings for the products and services with the goal of benefiting both staff and patients.” For more information, please visit www.medpricer.com. About Medpricer For more than a decade, Medpricer has helped move savings strategies forward with scalable purchased services solutions that improve sourcing efficiency and financial health. Their industry-leading software, mSource®, is the only all-in-one contract management, negotiation, and analytics platform that enables organizations to tailor contract terms to fit their unique needs – not those of a group. Engage with your purchasing data, learn from market intelligence, unite your stakeholders, and move contracts through the pipeline – faster. No catches, no [...]

View all news